This study aimed to analyse data from two different studies (phase II and phase III) regarding the safety and efficacy of treatment with alum formulated glutamic acid decarboxylase GAD65 (GAD-alum) at 30 months after administration to children and adolescents with type 1 diabetes.
GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30months(2013 Feb).
GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30months
2013
Abstract
This study aimed to analyse data from two different studies (phase II and phase III) regarding the safety and efficacy of treatment with alum formulated glutamic acid decarboxylase GAD65 (GAD-alum) at 30 months after administration to children and adolescents with type 1 diabetes.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR
